Pieris Pharmaceuticals Inc (PIRS)
15.95
-0.15
(-0.93%)
USD |
NASDAQ |
Nov 14, 16:00
15.69
-0.26
(-1.63%)
After-Hours: 20:00
Pieris Pharmaceuticals Research and Development Expense (Quarterly): 0.751M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.751M |
| March 31, 2024 | 1.218M |
| December 31, 2023 | 4.454M |
| September 30, 2023 | 9.595M |
| June 30, 2023 | 14.33M |
| March 31, 2023 | 13.42M |
| December 31, 2022 | 13.38M |
| September 30, 2022 | 13.59M |
| June 30, 2022 | 11.95M |
| March 31, 2022 | 14.07M |
| December 31, 2021 | 15.36M |
| September 30, 2021 | 18.94M |
| June 30, 2021 | 15.80M |
| March 31, 2021 | 16.56M |
| December 31, 2020 | 10.62M |
| September 30, 2020 | 11.82M |
| June 30, 2020 | 11.33M |
| March 31, 2020 | 12.76M |
| December 31, 2019 | 14.12M |
| Date | Value |
|---|---|
| September 30, 2019 | 13.21M |
| June 30, 2019 | 13.37M |
| March 31, 2019 | 14.30M |
| December 31, 2018 | 13.00M |
| September 30, 2018 | 11.40M |
| June 30, 2018 | 9.155M |
| March 31, 2018 | 7.936M |
| December 31, 2017 | 5.27M |
| September 30, 2017 | 6.259M |
| June 30, 2017 | 5.396M |
| March 31, 2017 | 5.36M |
| December 31, 2016 | 6.918M |
| September 30, 2016 | 4.622M |
| June 30, 2016 | 4.500M |
| March 31, 2016 | 3.659M |
| December 31, 2015 | 2.943M |
| September 30, 2015 | 2.052M |
| June 30, 2015 | 1.726M |
| March 31, 2015 | 1.525M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.751M
Minimum
Jun 2024
18.94M
Maximum
Sep 2021
11.79M
Average
13.38M
Median
Dec 2022
Research and Development Expense (Quarterly) Benchmarks
| Ligand Pharmaceuticals Inc | 5.675M |
| NovaBay Pharmaceuticals Inc | 0.004M |
| Palatin Technologies Inc | 4.672M |
| iBio Inc | 1.14M |
| Theriva Biologics Inc | 2.953M |